Biomarkers of Alzheimer's disease

被引:155
作者
Craig-Schapiro, Rebecca [1 ]
Fagan, Anne M. [1 ,3 ,4 ]
Holtzman, David M. [1 ,2 ,3 ,4 ]
机构
[1] Washington Univ, Dept Neurol, Sch Med, St Louis, MO 63110 USA
[2] Washington Univ, Dept Dev Biol, Sch Med, St Louis, MO 63110 USA
[3] Washington Univ, Hope Ctr Neurol Disorders, Sch Med, St Louis, MO 63110 USA
[4] Washington Univ, Alzheimer Dis Res Ctr, Sch Med, St Louis, MO 63110 USA
关键词
Alzheimer's disease; Amyloid-beta; Biomarker; Cerebrospinal fluid; Neumimaging; Proteomics; Tau; MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID-TAU; AMYLOID-BETA-PROTEIN; CEREBRAL-BLOOD-FLOW; POSITRON-EMISSION-TOMOGRAPHY; PITTSBURGH COMPOUND-B; NECROSIS-FACTOR-ALPHA; MEDIAL TEMPORAL-LOBE; NONDEMENTED ELDERLY SUBJECTS; AUTOPSY-CONFIRMED DEMENTIA;
D O I
10.1016/j.nbd.2008.10.003
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Although a battery of neuropsychological tests is often used in making a clinical diagnosis of Alzheimer's disease (AD), definitive diagnosis still relies on pathological evaluation at autopsy. The identification of AD biomarkers may allow for a less invasive and more accurate diagnosis as well as serve as a predictor of future disease progression and treatment response. Importantly, biomarkers may also allow for the identification of individuals who are already developing the underlying pathology of AD such as plaques and tangles yet who are not yet demented, i.e. "preclinical" AD. Attempts to identify biomarkers have included fluid and imaging studies, with a number of candidate markers showing significant potential. More recently, better reagent availability and novel methods of assessment have further spurred the search for biomarkers of AD. This review will discuss promising fluid and imaging markers to date. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:128 / 140
页数:13
相关论文
共 307 条
[1]  
Abdi F, 2006, J ALZHEIMERS DIS, V9, P293
[2]   IMMUNOCHEMICAL IDENTIFICATION OF THE SERINE PROTEASE INHIBITOR ALPHA-1-ANTICHYMOTRYPSIN IN THE BRAIN AMYLOID DEPOSITS OF ALZHEIMERS-DISEASE [J].
ABRAHAM, CR ;
SELKOE, DJ ;
POTTER, H .
CELL, 1988, 52 (04) :487-501
[3]  
AGDEPPA ED, 2001, J NUCL MED, V42
[4]   Inflammation and Alzheimer's disease [J].
Akiyama, H ;
Barger, S ;
Barnum, S ;
Bradt, B ;
Bauer, J ;
Cole, GM ;
Cooper, NR ;
Eikelenboom, P ;
Emmerling, M ;
Fiebich, BL ;
Finch, CE ;
Frautschy, S ;
Griffin, WST ;
Hampel, H ;
Hull, M ;
Landreth, G ;
Lue, LF ;
Mrak, R ;
Mackenzie, IR ;
McGeer, PL ;
O'Banion, MK ;
Pachter, J ;
Pasinetti, G ;
Plata-Salaman, C ;
Rogers, J ;
Rydel, R ;
Shen, Y ;
Streit, W ;
Strohmeyer, R ;
Tooyoma, I ;
Van Muiswinkel, FL ;
Veerhuis, R ;
Walker, D ;
Webster, S ;
Wegrzyniak, B ;
Wenk, G ;
Wyss-Coray, T .
NEUROBIOLOGY OF AGING, 2000, 21 (03) :383-421
[5]  
Alsop DC, 2000, ANN NEUROL, V47, P93, DOI 10.1002/1531-8249(200001)47:1<93::AID-ANA15>3.0.CO
[6]  
2-8
[7]   Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease:: a community based follow up study [J].
Andreasen, N ;
Vanmechelen, E ;
Van de Voorde, A ;
Davidsson, P ;
Hesse, C ;
Tarvonen, S ;
Räihä, I ;
Sourander, L ;
Winblad, B ;
Blennow, K .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 64 (03) :298-305
[8]   Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment [J].
Andreasen, N ;
Vanmechelen, E ;
Vanderstichele, H ;
Davidsson, P ;
Blennow, K .
ACTA NEUROLOGICA SCANDINAVICA, 2003, 107 :47-51
[9]   Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample [J].
Andreasen, N ;
Minthon, L ;
Clarberg, A ;
Davidsson, P ;
Gottfries, J ;
Vanmechelen, E ;
Vanderstichele, H ;
Winblad, B ;
Blennow, K .
NEUROLOGY, 1999, 53 (07) :1488-1494
[10]   Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease -: Differences between early- and late-onset Alzheimer disease and stability during the course of disease [J].
Andreasen, N ;
Hesse, C ;
Davidsson, P ;
Minthon, L ;
Wallin, A ;
Winblad, B ;
Vanderstichele, H ;
Vanmechelen, E ;
Blennow, K .
ARCHIVES OF NEUROLOGY, 1999, 56 (06) :673-680